Activision Blizzard Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Tempest Therapeutics Inc

Change company Symbol lookup

Select an option...

TPST Tempest Therapeutics Inc

PETV PetVivo Holdings Inc

KMI Kinder Morgan Inc

NXPL NextPlat Corp

D Dominion Energy Inc

CVS CVS Health Corp

CVI CVR Energy Inc

CTRE CareTrust REIT Inc

CSWC Capital Southwest Corp

CSCO Cisco Systems Inc

Health Care : Biotechnology |

Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Activision Blizzard Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

4:39 pm ET March 3, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Activision Blizzard Inc. (ATVI) rose 2.16% to $79.39 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.61% to 4,045.64 and the Dow Jones Industrial Average rising 1.17% to 33,390.97. This was the stock's second consecutive day of gains. Activision Blizzard Inc. closed $2.44 below its 52-week high ($81.83), which the company reached on March 4th.

The stock underperformed when compared to some of its competitors Friday, as Unity Software Inc. (U) rose 4.93% to $30.87. Trading volume (9.1 M) eclipsed its 50-day average volume of 5.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled March 3, 2023.

(END) Dow Jones Newswires

March 03, 2023 16:39 ET (21:39 GMT)